LRRK2 and Parkinson disease: Finally, sunitinib—a multi-kinase inhibitor that also inhibits LRRK2 kinase—is in clinical trial in order to establish an on-target assay for LRRK2 inhibitors as a therapeutic potential in PD (NCT01860118).